WallStreetZenWallStreetZen

NASDAQ: AKTX
Akari Therapeutics PLC Earnings & Revenue

AKTX earnings and revenue history

Current Revenue
$0.0
Current Earnings
$0.0
Current Profit Margin
0%

AKTX Return on Equity

Current Company
N/A
Current Industry
16.8%
Current Market
28.2%

Be the first to know when AKTX announces earnings.

AKTX Return on Assets

Current Company
N/A
Current Industry
3.2%

AKTX Return on Capital Employed

Current Company
0%
Current Industry
-42.4%

AKTX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
AKTXN/AN/AN/AN/AN/A
CLGN$10.62M-$6.89M-$7.50M+14.57%N/A
RLYB$0.00-$76.13M-$76.28MN/AN/A
PASG$0.00-$80.89M-$84.44MN/AN/A
IMMX$0.00-$18.15M-$18.21MN/AN/A

Akari Therapeutics Earnings & Revenue FAQ

What were AKTX's earnings last quarter?

On Invalid Date, Akari Therapeutics (NASDAQ: AKTX) reported Q1 2024 earnings per share (EPS) of $0.00, up N/A year over year. Total Akari Therapeutics earnings for the quarter were -$5.57 million. In the same quarter last year, Akari Therapeutics's earnings per share (EPS) was $0.00.

If you're new to stock investing, here's how to buy Akari Therapeutics stock.

What was AKTX's earnings growth in the past year?

As of Q3 2024, Akari Therapeutics's earnings has grown year over year. Akari Therapeutics's earnings in the past year totalled N/A.

What was AKTX's revenue last quarter?

On Invalid Date, Akari Therapeutics (NASDAQ: AKTX) reported Q1 2024 revenue of $0.00 up N/A year over year. In the same quarter last year, Akari Therapeutics's revenue was $0.00.

What was AKTX's revenue growth in the past year?

As of Q3 2024, Akari Therapeutics's revenue has grown null year over year. Akari Therapeutics's revenue in the past year totalled N/A.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.